The anti-HIV activity of (±)- cis-4,5-dihydroxy-1,2-dithiane 1,1-dioxide [(±)- cis-1,1-dioxo-[1,2]-dithiane-4,5-diol, NSC-624151] and its attack on the zinc finger domain of the HIV-1 nucleocapsid p7 (NCp7) protein has been established [Rice, W. G.; Baker, D. C.; Schaeffer, C. A.; Graham, L.; Bu, M.; Terpening, S.; Clanton, D.; Schultz, R.; Bader, J. P.; Buckheit, R. W.; Field, L.; Singh, P. K. Turpin, J. A. Antimicrob. Agents Chemother. 1997, 41, 419]. In order to determine which enantiomer of NSC-624151 is the more active component, the compound was resolved via its bis-‘Mosher ester’, which was prepared via its reaction with two equiv of (−)-( R)-α-methoxy-α-(trifluoromethyl)phenylacetyl chloride. The diastereoisomeric esters were separated, and each ester was hydrolyzed to yield enantiomers with α D 21 +151° ( c 0.5, MeOH) and α D 21 −146° ( c 0.5, MeOH). Single-crystal X-ray analysis of the (−)-bis-‘Mosher ester’ showed that the (−)-enantiomer is the (4 S, 5 R)-compound. The (−)-enantiomer (NSC 693195) was ca. twice as active (EC 50 8.8±0.2 μM) as its (+)-counterpart (NSC 693194) (EC 50 16.2±2.4 μM) in the XTT assay against HIV-1. All three compounds were found to be approximately equally effective in promoting Zn ejection from the NCp7 zinc finger. As the more anti-HIV active enantiomer is only slightly more active than the racemic form, it appears to offer no advantages over the racemic form.
Read full abstract